Welcome to our dedicated page for Fractyl Health news (Ticker: $GUTS), a resource for investors and traders seeking the latest updates and insights on Fractyl Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fractyl Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fractyl Health's position in the market.
Fractyl Health, Inc. (Nasdaq: GUTS) will present at BofA Securities 2024 Health Care Conference. Dr. Harith Rajagopalan, CEO, will participate in a fireside chat on May 15, 2024. The Company focuses on innovative treatments for obesity and type 2 diabetes.
Fractyl Health, Inc. (Nasdaq: GUTS) will report Q1 2024 financial results and business updates on May 13, 2024. The company focuses on metabolic therapeutics for obesity and T2D, hosting a conference call at 4:30 p.m. ET.
Fractyl Health, Inc. (Nasdaq: GUTS) will present new data at the German Diabetes Association (DDG) Annual Meeting on its real-world registry study of Revita for T2D and at the Digestive Disease Week (DDW) on the potential of Rejuva in reducing liver fat. The presentations include clinical updates and preclinical data demonstrating the effectiveness of their metabolic therapeutics in treating obesity and T2D.
